Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 3/20 | 0.33 |
| ▸ | PARP1 | P09874 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22859113 | 0.82 | PARP10 (0.51) | PARP10PARP11PARP1MAPTMAP2K1 | |
| SCHEMBL3840001 | 0.79 | PARP10 (0.36) | CLK4NTRK1FLT3GSK3BPIM1 | |
| SCHEMBL12951697 | 0.78 | KDR (0.37) | CLK4NTRK1FLT3GSK3BPIM1 | |
| SCHEMBL1476404 | 0.78 | MKNK2 (0.41) | CLK4NTRK1FLT3GSK3BDAPK3 | |
| SCHEMBL8154721 | 0.78 | PIK3CD (0.41) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL22491097 | 0.77 | IGF1R (0.38) | GSK3BPARP10PARP11AURKAKDR | |
| SCHEMBL21050756 | 0.70 | AURKA (0.40) | CLK4NTRK1FLT3GSK3BDAPK3 | |
| SCHEMBL25746072 | 0.70 | CLK4 (0.44) | CLK4NTRK1FLT3GSK3BDAPK3 | |
| SCHEMBL24771273 | 0.69 | SRD5A1 (0.36) | PARP10PARP11 | |
| SCHEMBL12654234 | 0.69 | AURKA (0.59) | CLK4NTRK1FLT3GSK3BDAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264844-A1 | HETEROCYCLIC GPR52 MODULATORS AND METHODS OF USE THEREOF | LIEBER INSTITUTE, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | AMGEN INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-117813086-A | Arylsulfonyl (hydroxy) piperidines as CCR6 inhibitors | 坎莫森特里克斯公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-3077008-B1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (CN) | 2023-10-04 | — | — | EP | disclosed |
| US-20230133406-A1 | Aryl Sulfonyl (Hydroxy) Piperidines as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-113166139-A | Pyrrolo [2,3-b ] pyridines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20150246958-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | BAIKANG (SUZHOU) CO., LTD (CN) | 2015-09-03 | — | — | US | disclosed |
| US-20150246958-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | BAIKANG (SUZHOU) CO., LTD (CN) | 2015-09-03 | — | — | US | disclosed |
| WO-2015081891-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | BAIKANG (SUZHOU) CO., LTD (CN) | 2015-06-11 | — | — | WO | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133406-A1 | Aryl Sulfonyl (Hydroxy) Piperidines as CCR6 Inhibitors | CCR6, CCR1, CCR4 | PIK3CD 4244/4885PIK3R1 3111/4885PIK3CA 3830/4885 |
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | CCR6, CCR1, CCR4 | PIK3CD 4244/4885PIK3R1 3111/4885PIK3CA 3830/4885 |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | PIK3CD 1029/4885PIK3R1 1014/4885PIK3CA 1203/4885 |
| US-20150246958-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | PIK3CD 3839/4885PIK3R1 3691/4885PIK3CA 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.